Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency
暂无分享,去创建一个
P. Ponikowski | I. Piña | G. Filippatos | T. Friede | M. Metra | J. Butler | G. Rosano | D. V. van Veldhuisen | E. Jankowska | A. Coats | U. Goehring | J. Comín-Colet | F. Dorigotti | Muhammad Shahzeb Khan | S. Anker | V. Fabien | G. Filippatos | E. Jankowska | M. S. Khan
[1] P. Ponikowski,et al. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial , 2021, European heart journal.
[2] P. Ponikowski,et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study , 2011, European heart journal.
[3] J. Spertus,et al. Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.
[4] P. Ponikowski,et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial , 2020, The Lancet.
[5] D. Girelli,et al. Anemia and iron deficiency in heart failure: extending evidences from chronic to acute setting , 2020, Internal and Emergency Medicine.
[6] P. Ponikowski,et al. Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction , 2020, European journal of heart failure.
[7] D. DeMets,et al. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction , 2019, Circulation.
[8] D. Silverberg,et al. Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure patients , 2019, ESC heart failure.
[9] S. Bhandari,et al. Intravenous Irons: From Basic Science to Clinical Practice , 2018, Pharmaceuticals.
[10] F. Verbrugge,et al. Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction , 2018, Acta cardiologica.
[11] B. Rocha,et al. The Burden of Iron Deficiency in Heart Failure: Therapeutic Approach. , 2018, Journal of the American College of Cardiology.
[12] P. Ponikowski,et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron‐deficient heart failure patients: an individual patient data meta‐analysis , 2018, European journal of heart failure.
[13] P. Ponikowski,et al. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency , 2017, Circulation.
[14] Akshay S. Desai,et al. Health-Related Quality of Life Outcomes in PARADIGM-HF , 2017, Circulation. Heart failure.
[15] Beat Flühmann,et al. The similarity question for biologicals and non-biological complex drugs. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[16] P. Ponikowski,et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency† , 2014, European heart journal.
[17] P. Ponikowski,et al. Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. , 2014, International journal of cardiology.
[18] D. Goff,et al. Cardiovascular Health : The Importance of Measuring Patient-Reported Health Status A Scientific Statement From the American Heart Association , 2022 .
[19] Vinod P. Shah,et al. Different Pharmaceutical Products Need Similar Terminology , 2013, The AAPS Journal.
[20] P. Ponikowski,et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. , 2011, Journal of cardiac failure.
[21] K. Swedberg,et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. , 2011, European Heart Journal.
[22] O. Nielsen,et al. Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A pilot study , 2010 .
[23] P. Ponikowski,et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. , 2009, The New England journal of medicine.
[24] W. Kraus,et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. , 2009, JAMA.
[25] P. Ponikowski,et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. , 2007, Journal of the American College of Cardiology.
[26] P. Duarte,et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. , 2007, Journal of the American College of Cardiology.
[27] A. Bolger,et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. , 2006, Journal of the American College of Cardiology.
[28] H. Krumholz,et al. Monitoring clinical changes in patients with heart failure: a comparison of methods. , 2005, American heart journal.
[29] J. Spertus,et al. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. , 2000, Journal of the American College of Cardiology.
[30] J. Hutton,et al. Number needed to treat: properties and problems , 2000 .